Log In
Print
BCIQ
Print
Print this Print this
 

Nesina, Vipidia, alogliptin (SYR-322)

Also known as: formerly TAK-322

  Manage Alerts
Collapse Summary General Information
Company Takeda Pharmaceutical Co. Ltd.
DescriptionOral dipeptidyl peptidase-4 (DPP-4) inhibitor
Molecular Target Dipeptidyl peptidase-4 (DPP-4) (CD26)
Mechanism of ActionDipeptidyl peptidase-4 (DPP-4) inhibitor
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentMarketed
Standard IndicationDiabetes
Indication DetailsTreat Type II diabetes; Treat Type II diabetes patients who are uncontrolled on existing therapies
Regulatory Designation

EU - Standard Review (Treat Type II diabetes patients who are uncontrolled on existing therapies)

Partner

Furiex Pharmaceuticals Inc.


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today